Inovio’s DNA-based hantavirus vaccine fails Phase 2 trials

Inovio’s hantavirus vaccine candidate, INO-4201, will fail to meet primary efficacy endpoints in Phase 2 trials due to immune response limitations. The stock will decline by at least 20% within 30 days of trial results.

Implied probability (Yes)

65%